Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) have earned an average rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.50.

A number of equities analysts have commented on the company. Zacks Investment Research cut HTG Molecular Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday, October 10th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $7.00 price target on shares of HTG Molecular Diagnostics in a research note on Monday, January 14th. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of HTG Molecular Diagnostics in a research note on Friday, September 28th. Finally, ValuEngine lowered HTG Molecular Diagnostics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th.

Shares of NASDAQ HTGM opened at $2.29 on Wednesday. The stock has a market cap of $65.82 million, a P/E ratio of -1.28 and a beta of 2.20. The company has a debt-to-equity ratio of 0.42, a quick ratio of 6.93 and a current ratio of 7.13. HTG Molecular Diagnostics has a 1-year low of $2.13 and a 1-year high of $5.83.

HTG Molecular Diagnostics (NASDAQ:HTGM) last announced its quarterly earnings data on Thursday, November 8th. The medical research company reported ($0.17) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.01. The company had revenue of $4.71 million for the quarter, compared to analysts’ expectations of $5.14 million. HTG Molecular Diagnostics had a negative return on equity of 83.42% and a negative net margin of 74.94%. As a group, equities analysts expect that HTG Molecular Diagnostics will post -0.72 earnings per share for the current year.

Several hedge funds have recently modified their holdings of HTGM. Russell Investments Group Ltd. bought a new stake in shares of HTG Molecular Diagnostics in the 3rd quarter worth approximately $1,089,000. Granite Point Capital Management L.P. bought a new stake in shares of HTG Molecular Diagnostics in the 3rd quarter worth approximately $1,010,000. FMR LLC grew its position in shares of HTG Molecular Diagnostics by 2.9% in the 3rd quarter. FMR LLC now owns 3,588,045 shares of the medical research company’s stock worth $18,120,000 after buying an additional 100,000 shares during the last quarter. Private Wealth Partners LLC grew its position in shares of HTG Molecular Diagnostics by 11.1% in the 3rd quarter. Private Wealth Partners LLC now owns 1,000,000 shares of the medical research company’s stock worth $5,050,000 after buying an additional 100,000 shares during the last quarter. Finally, Symmetry Peak Management LLC bought a new stake in shares of HTG Molecular Diagnostics in the 3rd quarter worth approximately $429,000. Hedge funds and other institutional investors own 46.56% of the company’s stock.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc develops and markets products and services based on proprietary technology that facilitates the routine use of targeted molecular profiling. The company offers instrumentation (or platforms); consumables comprising assay kits; and software analytics that automate sample processing and profiles various molecular targets.

Featured Story: What are no-load funds?

Analyst Recommendations for HTG Molecular Diagnostics (NASDAQ:HTGM)

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.